The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups - ArkVax, Paediatric HealthTech, ConcR and Stroma Biosciences - went head-to-head yesterday (Weds); competing for £10,000 additional funding generously donated by CMS Ventures in the Accelerate@Babraham with AstraZeneca: Start-up Pitching Competition.
Babraham Research Campus
The Babraham Research Campus is considered to be the UK’s leading campus to support early-stage bioscience enterprise. World class research and business come together to promote innovation and strengthen links between academia and the commercial world.
Telephone: +44 (0)1223 496 000
Address :
Babraham Bioscience Technologies Babraham Research Campus Babraham
Post Code: CB22 3AT
Country: United Kingdom
Website: http://www.babraham.com/
Membership Type: Cambridge University Department
Our mission is simple.
We will be the best place in Europe to start-up and scale-up a life science business. Our aim is to create an environment where companies can focus on developing their science and building their business in a supportive and highly networked community, helping to create new medicines, jobs and growth, and maximising the impact of UK science.
There are no Products & Services to display
26-11-2020
Closed Loop Medicine (CLM), a clinical stage therapeutics company developing drug + digital combination products, announces that the first patient has been recruited into its pivotal clinical trial investigating CLM’s integrated precision care solution for patients with hypertension.
23-11-2020
Cell Guidance Systems Ltd, a specialist in exosome research reagents and services, today announced the launch of a new product for the purification of exosomes from blood and other samples. The Exo-spin™ 96 exosome purification kit allows researchers to purify exosome samples in the standard 96 well plate format.
09-11-2020
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today reported financial results for the third quarter ended September 30, 2020 and discussed recent corporate updates.
06-11-2020
Babraham Bioscience Technologies (BBT), which is responsible for the management and commercial development of the Babraham Research Campus, today announced two new Board positions.
29-09-2020
The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups came together yesterday (Monday) for the first day of the 2020/21 programme.
22-09-2020
Atelerix Ltd, pioneers in the storage and transport of cells at room temperature, has received a significant award under the UK Innovation and Science Seed Fund (UKI2S) Accelerator Programme from Innovate UK, the UK’s innovation agency. The funding will support the development of room temperature solutions for shipping therapeutic cells, as part of the company’s “BloodReady” project.
03-09-2020
Reflection Therapeutics, Cambridge-based developer of cell therapy against neuroinflammation, is pleased to announce the start of a major Innovate Smart Grant project co-funded by Innovate UK, the UK’s innovation agency.
13-08-2020
Closed Loop Medicine has secured £250,000 from Innovate UK to support clinical evaluation of a drug + digital combination product for hypertension and COVID- 19 monitoring.
05-08-2020
Research led by an academic team from the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy.
16-06-2020
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announces its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge.
02-06-2020
Eisai joins AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the Babraham Research Campus bio-incubator programme, supporting early-stage science and new life science companies within the Cambridge cluster.
27-04-2020
A drug discovery business has announced that it will soon be able to complete 15,000 COVID-19 diagnostic tests per month in a bid to help the country combat the virus.
06-04-2020
Two start-up ventures share the inaugural LifeArc ‘Accelerate @Babraham Award'.
06-03-2020
PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, LifeArc.
02-03-2020
Babraham Investor Conference (BIC) is a must attend one-day conference for investors focusing on early-stage and scale-up life science and med-tech companies from across the UK and Europe.
03-02-2020
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), and AbbVie, a global, research-driven biopharmaceutical company, have announced the identification of several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration.
04-12-2019
Mundipharma joins AstraZeneca and LifeArc in providing funding for the continued development of the ‘Accelerate@Babraham’ initiative .
11-11-2019
LifeArc joins AstraZeneca in providing funding towards the continued development of the Babraham Research Campus’ Accelerate@Babraham initiative, which aims to nurture the development of early-stage science concepts and new life science companies.
23-09-2019
Five science start-ups have been awarded £10k, access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham, and will receive an extended programme of mentoring and support.
21-05-2019
Pages
There are no events to display
There are no jobs to display
No Blog articles found
